Cargando…

Antifungal therapy in patients with pulmonary Candida spp. colonization may have no beneficial effects

BACKGROUND: In critically ill patients, Candida spp. can often be identified in pulmonary samples. The impact of prompt antifungal therapy in these patients is unknown. METHODS: In this retrospective study, 500 adult patients with pulmonary Candida spp. colonization admitted to the intensive care un...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindau, Simone, Nadermann, Manuel, Ackermann, Hanns, Bingold, Tobias Michael, Stephan, Christoph, Kempf, Volkhard A. J., Herzberger, Pia, Beiras-Fernandez, Andres, Zacharowski, Kai, Meybohm, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490727/
https://www.ncbi.nlm.nih.gov/pubmed/26146563
http://dx.doi.org/10.1186/s40560-015-0097-0
_version_ 1782379560357068800
author Lindau, Simone
Nadermann, Manuel
Ackermann, Hanns
Bingold, Tobias Michael
Stephan, Christoph
Kempf, Volkhard A. J.
Herzberger, Pia
Beiras-Fernandez, Andres
Zacharowski, Kai
Meybohm, Patrick
author_facet Lindau, Simone
Nadermann, Manuel
Ackermann, Hanns
Bingold, Tobias Michael
Stephan, Christoph
Kempf, Volkhard A. J.
Herzberger, Pia
Beiras-Fernandez, Andres
Zacharowski, Kai
Meybohm, Patrick
author_sort Lindau, Simone
collection PubMed
description BACKGROUND: In critically ill patients, Candida spp. can often be identified in pulmonary samples. The impact of prompt antifungal therapy in these patients is unknown. METHODS: In this retrospective study, 500 adult patients with pulmonary Candida spp. colonization admitted to the intensive care unit (ICU) between 2010 and 2012 were included. The patients were analyzed according to whether or not they received antifungal therapy, which was administered at the discretion of the attending physician. Logistic regression analysis was performed to investigate the impact of antifungal therapy on hospital mortality and new onset of ventilator-associated pneumonia. In a stepwise backward elimination, the impact of age, cancer as an underlying disease, Simplified Acute Physiology Score (SAPS) II, and Sequential Organ Failure Assessment (SOFA) score were considered. RESULTS: After excluding 178 patients with multifocal Candida spp., isolated pulmonary Candida spp. colonization was found in 322 patients (cohort 1). Pre-existing pneumonia was found in 147/322 patients. Out of the remaining 175 patients (cohort 2), 44 patients received any antifungal therapy, and 131 were defined as the control group. Patients who received antifungal therapy had higher hospital mortality (50 vs. 30 %, p = 0.02) and pneumonia rates (47.7 vs. 16.8 %; p < 0.001) than those who did not. In Cox regression analysis, antifungal therapy was not independently associated with favorable outcome (mortality: odds ratio 0.854 (95 % CI 0.467–1.561); new pneumonia: 1.048 (0.536–2.046)), but SAPS II and SOFA score were significantly (p < 0.05) independent covariates for worse outcome. CONCLUSIONS: In critically ill patients with pulmonary Candida spp. colonization, antifungal therapy may not have an impact on the incidence of new pneumonia or in-hospital mortality after adjustment for confounders. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40560-015-0097-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4490727
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44907272015-07-04 Antifungal therapy in patients with pulmonary Candida spp. colonization may have no beneficial effects Lindau, Simone Nadermann, Manuel Ackermann, Hanns Bingold, Tobias Michael Stephan, Christoph Kempf, Volkhard A. J. Herzberger, Pia Beiras-Fernandez, Andres Zacharowski, Kai Meybohm, Patrick J Intensive Care Research Article BACKGROUND: In critically ill patients, Candida spp. can often be identified in pulmonary samples. The impact of prompt antifungal therapy in these patients is unknown. METHODS: In this retrospective study, 500 adult patients with pulmonary Candida spp. colonization admitted to the intensive care unit (ICU) between 2010 and 2012 were included. The patients were analyzed according to whether or not they received antifungal therapy, which was administered at the discretion of the attending physician. Logistic regression analysis was performed to investigate the impact of antifungal therapy on hospital mortality and new onset of ventilator-associated pneumonia. In a stepwise backward elimination, the impact of age, cancer as an underlying disease, Simplified Acute Physiology Score (SAPS) II, and Sequential Organ Failure Assessment (SOFA) score were considered. RESULTS: After excluding 178 patients with multifocal Candida spp., isolated pulmonary Candida spp. colonization was found in 322 patients (cohort 1). Pre-existing pneumonia was found in 147/322 patients. Out of the remaining 175 patients (cohort 2), 44 patients received any antifungal therapy, and 131 were defined as the control group. Patients who received antifungal therapy had higher hospital mortality (50 vs. 30 %, p = 0.02) and pneumonia rates (47.7 vs. 16.8 %; p < 0.001) than those who did not. In Cox regression analysis, antifungal therapy was not independently associated with favorable outcome (mortality: odds ratio 0.854 (95 % CI 0.467–1.561); new pneumonia: 1.048 (0.536–2.046)), but SAPS II and SOFA score were significantly (p < 0.05) independent covariates for worse outcome. CONCLUSIONS: In critically ill patients with pulmonary Candida spp. colonization, antifungal therapy may not have an impact on the incidence of new pneumonia or in-hospital mortality after adjustment for confounders. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40560-015-0097-0) contains supplementary material, which is available to authorized users. BioMed Central 2015-07-03 /pmc/articles/PMC4490727/ /pubmed/26146563 http://dx.doi.org/10.1186/s40560-015-0097-0 Text en © Lindau et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Lindau, Simone
Nadermann, Manuel
Ackermann, Hanns
Bingold, Tobias Michael
Stephan, Christoph
Kempf, Volkhard A. J.
Herzberger, Pia
Beiras-Fernandez, Andres
Zacharowski, Kai
Meybohm, Patrick
Antifungal therapy in patients with pulmonary Candida spp. colonization may have no beneficial effects
title Antifungal therapy in patients with pulmonary Candida spp. colonization may have no beneficial effects
title_full Antifungal therapy in patients with pulmonary Candida spp. colonization may have no beneficial effects
title_fullStr Antifungal therapy in patients with pulmonary Candida spp. colonization may have no beneficial effects
title_full_unstemmed Antifungal therapy in patients with pulmonary Candida spp. colonization may have no beneficial effects
title_short Antifungal therapy in patients with pulmonary Candida spp. colonization may have no beneficial effects
title_sort antifungal therapy in patients with pulmonary candida spp. colonization may have no beneficial effects
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490727/
https://www.ncbi.nlm.nih.gov/pubmed/26146563
http://dx.doi.org/10.1186/s40560-015-0097-0
work_keys_str_mv AT lindausimone antifungaltherapyinpatientswithpulmonarycandidasppcolonizationmayhavenobeneficialeffects
AT nadermannmanuel antifungaltherapyinpatientswithpulmonarycandidasppcolonizationmayhavenobeneficialeffects
AT ackermannhanns antifungaltherapyinpatientswithpulmonarycandidasppcolonizationmayhavenobeneficialeffects
AT bingoldtobiasmichael antifungaltherapyinpatientswithpulmonarycandidasppcolonizationmayhavenobeneficialeffects
AT stephanchristoph antifungaltherapyinpatientswithpulmonarycandidasppcolonizationmayhavenobeneficialeffects
AT kempfvolkhardaj antifungaltherapyinpatientswithpulmonarycandidasppcolonizationmayhavenobeneficialeffects
AT herzbergerpia antifungaltherapyinpatientswithpulmonarycandidasppcolonizationmayhavenobeneficialeffects
AT beirasfernandezandres antifungaltherapyinpatientswithpulmonarycandidasppcolonizationmayhavenobeneficialeffects
AT zacharowskikai antifungaltherapyinpatientswithpulmonarycandidasppcolonizationmayhavenobeneficialeffects
AT meybohmpatrick antifungaltherapyinpatientswithpulmonarycandidasppcolonizationmayhavenobeneficialeffects